Sartorius confirms FY 2026 sales growth outlook of 5%-9%

Leverage Shares 2X Long SATS Daily ETF

Leverage Shares 2X Long SATS Daily ETF

SATG

0.00
  • Sartorius Stedim Biotech confirmed FY 2026 guidance for sales revenue growth of about 5% to 9% in constant currencies.
  • Underlying EBITDA margin still seen slightly above 30% for the group.
  • Guidance includes about 0.3 percentage points of growth from MATTEK; group expects net debt to underlying EBITDA slightly above 3x.
  • H1 2026 operational sales growth was 7.7%, with sales revenue of EUR 1.81 billion; underlying EBITDA margin rose to 30.3%.
  • Tariff-related customer compensation of EUR 26 million in Q2 weighed on reported growth; further refund applications total EUR 40 million, with EUR 14 million outstanding.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sartorius Stedim Biotech SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.